ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against
metastatic breast cancer. However, the Taxol formulation requires prolonged administration
times, and there are safety problems that have been attributed to the solvent rather than the
active ingredient, paclitaxel. This is a new formulation of paclitaxel that has been found to
have fewer safety problems than Taxol, and may be administered safely at higher doses. This
study will investigate the safety and efficacy of this new formulation of paclitaxel given
intravenously once a week for three weeks, followed by a rest week. This cycle will be
repeated until safety problems or treatment failure require that the patient stop therapy.